Chemotherapy is not an ideal treatment for NSCLC patients with MET exon 14 skipping mutation as the OS of patients receiving first-line chemotherapy is only 6.7 months.[5] In terms of immunotherapy, a study of 147 NSCLC patients with MET exon 14 skipping mutations showed that: 63% of patients had positive expression of programmed death ligand 1 (PD-L1) (TPS ≥ 1%) while the level of tumor mutational burden (TMB) expression was generally low. Here, MET is linked to neoplasm.